Serum Level Of CRP Predicts Response To Adalimumab Treatment For Patients With Hidradenitis Suppurativa, Analysis Finds

MedPage Today (1/12, Kneisel) reports, “Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa, post hoc analysis of the PIONEER I and II trials found.” Researchers found that “at 12 weeks of follow-up, adults with elevated CRP (defined as >0.30 mg/dL) at baseline – whose disease was also more severe – had lower odds of clinical response.” The investigators said, “Our findings suggest that adalimumab may be less effective in patients with the most severe inflammatory load.” The findings were published in JAMA Dermatology.